Methods of treating endometriosis, adenomyosis, or dysmenorrhea in a subject using PEMF device
The PEMF device addresses the challenge of treating endometriosis, adenomyosis, and dysmenorrhea by applying electromagnetic fields to modulate cellular ion channels and promote healing, reducing pain through synaptic membrane modulation and enhancing tissue repair.
Patent Information
- Application Number
- PCT/US2026/027074
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-19
AI Technical Summary
Pain associated with endometriosis, adenomyosis, and dysmenorrhea is difficult to treat due to the subjective nature of pain perception and the inability to define and quantify it effectively, leading to challenges in selecting appropriate treatment methods.
A pulsed electromagnetic field (PEMF) device is positioned at or near the site of pain, applying electromagnetic fields at specific frequencies and durations to modulate cellular ion channels, reduce pain signal transmission, and promote tissue healing.
The PEMF device effectively reduces perceived pain by lowering the resting potential of synaptic membranes, inhibiting pain signal transmission, and supporting tissue repair through enhanced blood flow and nutrient delivery.
Smart Images

Figure 00000028_0000 
Figure 00000029_0000 
Figure 00000030_0000
Abstract
Description
Attorney Docket No.: 189577-010101 / PCT Electronically Filed: May 7, 2026 METHODS OF TREATING ENDOMETRIOSIS, ADENOMYOSIS, OR DYSMENORRHEA IN A SUBJECT USING PEMF DEVICEPRIORITY
[0001] This application claims priority to and the benefit of U.S. Patent Application No.19 / 205,336, filed on May 12, 2025, the contents of which is incorporated herein by reference in its entirety.FIELD
[0002] This invention relates to methods of treating endometriosis, adenomyosis, or dysmenorrhea in a subject using a pulsed electromagnetic field device.BACKGROUND
[0003] Pain is felt when nerves that detect tissue damage send electrical signals along the spinal cord to the brain to transmit information about the damage. Pain can be reduced by minimizing or eliminating the damage, or by reducing or blocking the pain signals en route to the brain. However, the experience of pain is different for everyone, and there are different ways of feeling and describing pain. This makes pain difficult to define, quantify, and treat.SUMMARY
[0004] Some embodiments relate to a method. In some embodiments, the method for treating endometriosis adenomyosis, or dysmenorrhea in a subject in need thereof comprises positioning a pulsed electromagnetic field device at or near a site of pain. In some embodiments, the site of pain is at least one of an abdomen, a pelvis, a lower back, or any combination thereof. In some embodiments, the method for treating endometriosis, adenomyosis, or dysmenorrhea in a subject in need thereof comprises applying a treatment protocol. In some embodiments, the treatment protocol comprises applying a first electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, the first electromagnetic fieldis administered at a nominal frequency in a range of 40 Hz to 70 Hz. In some embodiments, the treatment protocol comprises applying a second electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, the second electromagnetic field is administered at a nominal frequency in a range of 70 Hz to 175 Hz. In some embodiments, the treatment protocol is applied for a time period of about 20 minutes to 360 minutes.
[0005] Some embodiments relate to a method. In some embodiments, a method for treating endometriosis, adenomyosis, or dysmenorrhea in a subject in need thereof comprises positioning a pulsed electromagnetic field device at or near a site of pain. In some embodiments, the site of pain is at least one of an abdomen, a pelvis, a lower back, or any combination thereof. In some embodiments, the method for treating endometriosis, adenomyosis, or dysmenorrhea in a subject in need thereof comprises applying a treatment protocol. In some embodiments, the method comprises applying an electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, the electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 175 Hz for at time period of 20 minutes to 360 minutes.DRAWINGS
[0006] FIG. 1 is a flowchart of a method, according to some embodiments.
[0007] FIG. 2 is a schematic diagram of a PEMF device, according to some embodiments.
[0008] FIG. 3 is a schematic diagram of a PEMF device docking station, according to some embodiments.
[0009] FIGS. 4A and 4B are schematic diagrams of a PEMF device strap, according to some embodiments.DETAILED DESCRIPTION
[0010] Among those benefits and improvements that have been disclosed, other objects and advantages of this disclosure will become apparent from the following description taken in conjunction with the accompanying figures. Detailed embodiments of the present disclosure are disclosed herein; however, it is to be understood that the disclosed embodiments are merely illustrative of the disclosure that may be embodied in various forms. In addition, each of the examples given regarding the various embodiments of the disclosure which are intended to be illustrative, and not restrictive.
[0011] Any prior patents and publications referenced herein are incorporated by reference in their entireties.
[0012] Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrases “in one embodiment,” “in an embodiment,” and “in some embodiments” as used herein do not necessarily refer to the same embodiment(s), though it may. Furthermore, the phrases “in another embodiment” and “in some other embodiments” as used herein do not necessarily refer to a different embodiment, although it may. All embodiments of the disclosure are intended to be combinable without departing from the scope or spirit of the disclosure.
[0013] As used herein, the term "based on" is not exclusive and allows for being based on additional factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of "a," "an," and "the" include plural references. The meaning of "in" includes "in" and "on."
[0014] Pain developed from diseases of the pelvic area, such as endometriosis, adenomyosis, primary dysmenorrhea, chronic pelvic pain syndrome, interstitial cystitis, or chronic prostatitis can be difficult to treat. Depending on the type of endometriosis or adenomyosis, the pain level a subject experiences will vary. The pain experienced from these diseases of the pelvic area can be associated with nociceptive pain caused by tissue damage, or as a result of altered nociception. For instance, endometriosis, an estrogen-driven chronic inflammatory disease,develops as a result of endometrial-like cells that colonize outside of the uterus and result in lesions. Where pain is experienced can indicate where the inflammation has developed. Pain is often treated through hormonal therapy, pain medicine, surgery, and hysterectomy. Due to an inability to define and quantify pain, choosing the appropriate treatment can be difficult. The embodiments disclosed herein overcome these challenges by providing an alternate method of treating endometriosis, adenomyosis, or dysmenorrhea using a pulsed electromagnetic field (PEMF) device.
[0015] In some embodiments, the resting state of a cell is about -70 millivolts (mV). In some embodiments, a small amount of energy can be used to modulate a cell membrane in order to open transporter channels to allow the exchange of sodium, potassium, and calcium ions. In some embodiments, the PEMF device can mimic and replace the body of a subject own endogenous electrical energy that is naturally produced when tissue is subject to dynamic loading but missing in the case of injury or degenerative issues. In some embodiments, pain signals are transferred to the brain via chemical signals that travel across synaptic gaps. For example, in some embodiments, the resting potential of a synaptic membrane is about -70 mV. In some embodiments, a pain signal can raise the resting potent of the synaptic membrane to about +30 mV. By applying a treatment protocol, described herein, an electromagnetic signal at the area being treated, the PEMF device can lower the resting state to a hyper- polarized level of about -90 mV. In some embodiments, the pain signal does not raise the resting potential enough to trigger the release of chemical transmitter signals, the pain signals, thereby bringing about a reduction in perceived pain.
[0016] FIG. 1 is a flowchart of a method of treating endometriosis, adenomyosis, or dysmenorrhea according to some embodiments. In some embodiments, the method comprises the steps of: positioning 102 a pulsed electromagnetic field device at or near a site of pain, and applying 104 a treatment protocol.
[0017] At step 102, in some embodiments, a method for treating endometriosis, adenomyosis, or dysmenorrhea in a subject in need thereof comprises positioninga pulsed electromagnetic field device at or near a site of pain. In some embodiments, positioning comprises placing the pulsed electromagnetic field device at or near a site of pain. In some embodiments, positioning comprising arranging the pulsed electromagnetic field device at or near a site of pain. In some embodiments, positioning comprising aligning the pulsed electromagnetic field device at or near a site of pain. In some embodiments, positioning comprising orienting the pulsed electromagnetic field device at or near a site of pain. In some embodiments, positioning comprising setting the pulsed electromagnetic field device at or near a site of pain. In some embodiments, positioning comprising placing the pulsed electromagnetic field device at or near a site of pain.
[0018] In some embodiments, the pain is at least one of nociceptive pain, neuropathic pain, nociplastic pain, or any combination thereof. For example, in some embodiments, for endometriosis, the nociceptive pain caused by inflammation can be accompanied by nociplastic pain due to a reduced pain threshold and neurogenic inflammation.
[0019] In some embodiments, the site of pain is at least one of an abdomen, a pelvis, a back, a side, a chest, a neck, a diaphragm, or any combination thereof.
[0020] As shown in FIG. 2, in some embodiments, the PEMF device 10 comprises a top housing 11 and a mated bottom housing 15 that form a coil housing that encases a coil 14 and a printed circuit board 12 ("PCB 12"). In some embodiments, a display 13 can be electrically connected to the PCB 12 and is visible through the top housing 11. In some embodiments, the display can be a liquid crystal display but may also be a light emitting diode ("LED") display or transparent light guide that directs light from edge-mounted LEDs down toward the surface of the display. In some embodiments, a button 19 can be accessible on the coil housing. In some embodiments, pressing button 19 can cause a treatment protocol name, for the method for treating endometriosis, adenomyosis, or dysmenorrhea described herein, to be displayed on the display 13. In some embodiments, if the treatment protocol is selected, the treatment protocol can be activated. In some embodiments, the button 19 can be mechanical. In some embodiments, the button19 can give a tactile response when depressed. In some embodiments, the PEMF device 10 can be capacitive and give an audible response when depressed. In some embodiments, light emitting diodes 17 ("LEDs 17") are visible through the coil housing to indicate when the device is emitting energy.
[0021] In some embodiments, the PEMF device 10 can be powered by a battery 18, sandwiched between the bottom housing 15 and a battery cover 16 attached to the bottom housing 15. In some embodiments, the PEMF device 10 uses a Li-ion 3.7 or 4.2V battery that, under normal operating conditions, can provide about 2 to 30 applications of 30 minutes each before running out of energy. In some embodiments, the battery 18 can be rechargeable. In some embodiments, the battery 18 can be removable.
[0022] FIG. 3 is a schematic diagram of a PEMF device docking station, according to some embodiments. In some embodiments, the PEMF device 10 can be coupled with a docking station 21 for recharge from mains power via charging terminals 22 while the device is seated in the docking station 22. In some embodiments, a USB port enables the battery 18 to be charged while the PEMF device 10 is connected to a power source via a USB cable.
[0023] In some embodiments, as shown in FIG. 2, the coil 14, display 13, button 19, and battery 18 are in electrical communication with PCB 12. In some embodiments, the circuitry on the PCB 12 can cause the desired electromagnetic field to be generated from the coil 14. In some embodiments, the coil 14 can comprise an electrical conductor between 18 and 40 gauge and can be relatively rigid. In some embodiments, the coil 14 can be copper. In some embodiments, the coil 14 can be any electrically conductive material. For example, in some embodiments, the coil 14 can be insulated enameled copper wire having a diameter of about 0.315 mm or roughly 28 gauge and can be wrapped with 70 turns around four anchoring posts A, B, C, and D. In some embodiments, the distance between anchor posts A and D is 83 mm. In some embodiments, the distance between anchor posts B and C is 83 mm. In some embodiments, the distance between anchor posts A and B is 30 mm. In some embodiments, the distance between anchor posts C and Dis 30 mm. In some embodiments, the coil 14 comprises about 1,750 cm of wire. In some embodiments, the coil 14 is 45 mm at its extreme width and 95 mm at its extreme length. In some embodiments, the coil is wrapped with 76 turns around four anchoring posts A, B, C, and D, and the coil 14 is 50 mm at its extreme width and 100 mm at its extreme length In some embodiments, the ends of the wire are electrically connected to the PCB 12 by solder. In some embodiments, the resistance of the coil 14 is about 5 Ohms. In some embodiments, PEMF device 10 does not comprise a magnetic shield.
[0024] In some embodiments, the PEMF device 10 is small. In some embodiments, the PEMF device 10 can be in the shape of at least one of rounded rectangle, egg- shaped, circular, square, toroidal, or any combination thereof. For example, in some embodiments, the PEMF device 10 is in the shape of a rounded rectangle of about 3x5 inches. In some embodiments, the PEMF device 10 comprises materials that make the device lightweight. For example, in some embodiments, the PEMF device 10 weighs about 2 ounces, using a plastic housing and a Li-ion battery.
[0025] In some embodiments, the PEMF device 10 can be used external to the body. In some embodiments, the PEMF device 10 does have direct contact with skin. In some embodiments, the PEMF device 10 does not have direct contact with skin. In some embodiments, the PEMF device 10 does not use wires, terminals, or pads to connect to the user. In some embodiments, the PEMF device 10 can emit the pulsed electromagnetic field to treat an area of the body.
[0026] In some embodiments, the PEMF device 10 can provide a treatment range of 0.1 inches to 11 inches in each direction of the source of the pain, or any range or subrange between 0.1 inches to 11 inches. For example, in some embodiments, the PEMF device 10 can provide a treatment range of 1 inches to 10 inches, 2 inches to 9 inches, 3 inches to 8 inches, 4 inches to 7 inches, or 5 inches to 6 inches in each direction of the source of the pain. In some embodiments, the PEMF device 10 can provide a treatment range of 1 inches to 11 inches, 3 inches to 11 inches, 5 inches to 11 inches, 7 inches to 11 inches, or 9 inches to 11 inches ineach direction of the source of the pain. In some embodiments, the PEMF device 10 can provide a treatment range of 0.1 inches to 9 inches, 0.1 inches to 7 inches, 0.1 inches to 5 inches, 0.1 inches to 3 inches, or 0.1 inches to 1 inches in each direction of the source of the pain.
[0027] In some embodiments, the PEMF device 10 can provide a treatment range of 0.1 inches to 22 inches in diameter from the source of the pain, or any range or subrange between 0.1 inches to 22 inches. For example, in some embodiments, the PEMF device 10 can provide a treatment range of 2 inches to 20 inches, 4 inches to 18 inches, 6 inches to 16 inches, 8 inches to 14 inches, or 10 inches to 12 inches in diameter from the source of the pain. In some embodiments, the PEMF device 10 can provide a treatment range of 2 inches to 20 inches, 4 inches to 18 inches, 6 inches to 16 inches, 8 inches to 14 inches, or 10 inches to 12 inches in diameter from the source of the pain. In some embodiments, the PEMF device 10 can provide a treatment range of 0.1 inches to 20 inches, 0.1 inches to 18 inches, 0.1 inches to 16 inches, 0.1 inches to 14 inches, 0.1 inches to 12 inches, 0.1 inches to 10 inches, 0.1 inches to 8 inches, 0.1 inches to 6 inches, 0.1 inches to 4 inches, or 0.1 inches to 2 inches in diameter from the source of the pain.
[0028] In some embodiments, the PEMF device 10 can be worn over clothing, placed in an adjacent pocket, or behind the user's back in a chair while the user is watching TV or driving. In some embodiments, the pulsed electromagnetic field signals can travel through materials used to cast body parts such as plaster and fiberglass, with minimum field displacement by metals such as titanium used in joint replacement surgery. In some embodiments, the PEMF device 10 can be portable and usable during normal daily activities.
[0029] In some embodiments, the PEMF device 10 can be held in place simply by resting it on or near the desired area of treatment. For example, for back treatment, the device can be placed on the back using a long wrap. In some embodiments, the PEMF device 10 can be placed on the body by using a long wrap for the torso, or a short wrap for extremities. In some embodiments, the PEMF device 10 can be used during work, play and other regular daily activities. In some embodiments,the PEMF device 10 can be attached to the user for unattended portability. For example, in some embodiments, the PEMF device 10 can be held in place using an elastic strap to surround the device and the treated body part, compressing the device between the strap and the body. As shown in FIGS. 4A and 4B, in some embodiments, the PEMF device 10 can be held in place using a strap 30 that is woven through one or more strap slots 31 on the exterior of the device 10. In some embodiments, the strap 30 may be tightened and secured using a buckle or a hook 32 and loop 33 material such as Velcro®.
[0030] In some embodiments, the parameters of the electromagnetic field can be prescribed by a plurality of protocols stored in and executable sequentially by the circuitry on the PCB 12. In some embodiments, pulses of energy at discrete frequencies can be arranged in a unique sequential protocol programming format in order to deliver effective treatment. In some embodiments, the PEMF device 10 can provide dynamic feedback during treatments, using visual indicators such as flashing or steady light provided by light-emitting diodes, audible indicators such as buzzes or beeps, or indicators directed to the sense of touch. For example, in some embodiments, the PEMF device 10 can use a haptic module to provide vibrational feedback during treatments. In some embodiments, the PEMF device 10 can vibrate at a given frequency the entire time it is emitting energy, or at the start and end of a treatment. In some embodiments, the PEMF device 10 can vibrate at a different frequency each time the treatment frequency changes. In some embodiments, the PEMF device 10 can provide the user the capability to control alerts.
[0031] In some embodiments, the pulsed electromagnetic field device is in operation for a time period of about 1 minute to 360 minutes, or any range or subrange between 1 minute and 360 minutes. For example, in some embodiments, the pulsed electromagnetic field device is in operation for a time period of about 30 minutes to 330 minutes, 60 minutes to 300 minutes, 90 minutes to 270 minutes, 120 minutes to 240 minutes, or 150 minutes to 210 minutes. In some embodiments, the pulsed electromagnetic field device is in operation for a time period of about 1 minute to 330 minutes, 1 minute to 300 minutes, 1 minute to 270 minutes, 1 minuteto 240 minutes, 1 minute to 210 minutes, 1 minute to 180 minutes, 1 minute to 150 minutes, 1 minute to 120 minute, 1 minute to 90 minutes, 1 minute to 60 minutes, or 1 minute to 30 minutes. In some embodiments, the pulsed electromagnetic field device is in operation for a time period of about 30 minutes to 360 minutes, 60 minutes to 360 minutes, 90 minutes to 360 minutes, 120 minutes to 360 minutes, 150 minutes to 360 minutes, 180 minutes to 360 minutes 210 minutes to 360 minutes, 240 minutes to 360 minutes, 270 minutes to 360 minutes, 300 minutes to 360 minutes, or 330 minutes to 360 minutes.
[0032] At step 104, in some embodiments, the method for treating endometriosis, adenomyosis, or dysmenorrhea in a subject in need thereof comprises applying a treatment protocol. In some embodiments, applying comprising using the treatment protocol. In some embodiments, applying comprising administering the treatment protocol.
[0033] In some embodiments, the treatment protocol comprises at least one of a 3-phase treatment protocol, a 4-phase treatment protocol, a 5-phase treatment protocol, or any combination thereof. In some embodiments, the 3-phase treatment protocol comprises applying a first electromagnetic field at an Angio frequency, applying a second electromagnetic field at a pain frequency, and applying the first electromagnetic field at the Angio frequency. In some embodiments, the 4-phase treatment protocol comprises applying a first electromagnetic field at an Angio frequency, applying a post-first electromagnetic field at an Osseus frequency, applying a pre-second electromagnetic field at an Chondro frequency, and applying a second electromagnetic field at an pain frequency. In some embodiments, the 5-phase treatment protocol comprises applying a first electromagnetic field at an Angio frequency, applying a post-first electromagnetic field at an Osseus frequency, applying a pre-second electromagnetic field at an Chondro frequency, applying a second electromagnetic field at an Osseus frequencyand applying the first electromagnetic field at an Angio frequency.
[0034] In some embodiments, the treatment protocol can comprise applying a first electromagnetic field at or near the site of pain in the subject in need thereof. Insome embodiments, the selection of first electromagnetic field nominal frequency range is based on its efficacy in modulating ion channels and cellular signaling, which are important for reducing inflammation and promoting tissue repair. In some embodiments, the first electromagnetic field is configured to target an inflammatory phase of an endometrial tissue. In some embodiments, the precise frequency within the range can be adjusted to optimize therapeutic outcomes, taking into account the sensitivity of low frequencies to timing and biological response. In some embodiments, the application of the first electromagnetic field mimics the body's natural electrical activity, thereby enhancing blood flow and nutrient delivery to the affected area, which assists in alleviating pain and supporting the healing process. For example, in some embodiments, Angio frequency, short for Angiogenesis, can be emitted at the first electromagnetic field. In some embodiments, Angio frequency can correspond to the first phase of biological repair and can be the physiological process through which new blood vessels form from pre-existing vessels. In some embodiments, the Angio frequency can be used to increase capillary dilation and thus increase blood flow, which can provide more oxygen and nutrients to the area being treated. In some embodiments, the Angio frequency can be used for treating inflammation, and bruising.
[0035] In some embodiments, the first electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 70 Hz, or any range or subrange between 40 Hz and 70 Hz. For example, in some embodiments, the first electromagnetic field is administered at a nominal frequency in a range of 45 Hz to 65 Hz, 50 Hz to 60 Hz, 40 Hz to 65 Hz, 40 Hz to 60 Hz, 40 Hz to 55 Hz, 40 Hz to 50 Hz, or 40 Hz to 45 Hz. In some embodiments, the first electromagnetic field is administered at a nominal frequency in a range of 45 Hz to 70 Hz, 50 Hz to 70 Hz, 55 Hz to 70 Hz, 60 Hz to 70 Hz, or 65 Hz to 70 Hz.
[0036] The treatment protocol can comprise applying a second electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, pain frequency can be emitted at the second electromagnetic field. In some embodiments, the selection of the second electromagnetic field nominal frequency range is based on the demonstrated efficacy to interact with neural pathwaysresponsible for pain perception. In some embodiments, the second electromagnetic field is configured to target a pain phase of an endometrial tissue. In some embodiments, the high-frequency range of the second electromagnetic field, can be effective in modulating nerve activity, thereby reducing the transmission of pain signals to the brain. In some embodiments, the modulation of nerve activity can be achieved by influencing the synaptic transmission processes, which are sensitive to electromagnetic fields within this frequency range. In some embodiments, the capability of the second electromagnetic field to target broader neural systems allows for a degree of frequency variance without impacting therapeutic outcomes, making the second electromagnetic field a robust component of the overall treatment protocol for endometriosis, adenomyosis, or dysmenorrhea.
[0037] In some embodiments, the second electromagnetic field is administered at a nominal frequency in a range of 70 Hz to 175 Hz, or any range or subrange between 125 Hz and 185 Hz. For example, in some embodiments, the second electromagnetic field is administered at a nominal frequency in a range of, 80 Hz to 165 Hz, 90 Hz to 155 Hz, 100 Hz to 145 Hz, 110 Hz to 135 Hz, 120 HZ to 125 Hz. In some embodiments, the second electromagnetic field is administered at a nominal frequency in a range of 80 Hz to 175 Hz, 90 Hz to 175 Hz, 100 Hz to 175 Hz, 110 Hz to 175 Hz, 120 Hz to 175 Hz, 130 Hz to 175 Hz, 140 Hz to 175 Hz, 150 Hz to 175 Hz, 160 Hz to 175 Hz, or 170 Hz to 175 Hz. In some embodiments, the second electromagnetic field is administered at a nominal frequency in a range of 70 Hz to 175 Hz, 70 Hz to 165 Hz, 70 Hz to 155 Hz, 70 Hz to 145 Hz, 70 Hz to 135 Hz, 70 Hz to 125 Hz, 70 Hz to 115 Hz, 70 Hz to 105 Hz, 70 Hz to 95 Hz, 70 Hz to 85 Hz, or 70 Hz to 75 Hz.
[0038] In some embodiments, a treatment protocol can comprise oscillating between the first electromagnetic field and the second electromagnetic field.
[0039] In some embodiments, in a 4-phase protocol, or in a 5-phase protocol, the treatment protocol can comprise applying a post-first electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, the post-first electromagnetic field does not directly target endometrial tissue. In some embodiments, the selection of the post-first electromagnetic field nominal frequency range is based on the efficacy in supporting osseous tissue. In some embodiments, the post-first electromagnetic field enhances cellular signaling and modulate ion channels, which can assist in reducing inflammation and promoting tissue repair. In some embodiments, by targeting biological processes such as cellular signaling and ion channels, the post-first electromagnetic field can contribute to the overall therapeutic effect, helping to alleviate pain and support the healing of affected tissues.
[0040] In some embodiments, the post-first electromagnetic field is administered at a nominal frequency in a range of 10 Hz to 20 Hz, or any range or subrange between 12 Hz and 18 Hz. For example, in some embodiments, the post-first electromagnetic field is administered at a nominal frequency in a range of 11 Hz to 19 Hz, 12 Hz to 18 Hz, 13 Hz to 17 Hz, 14 Hz to 16 Hz, 11 Hz to 20 Hz, 12 Hz to 20 Hz, 13 Hz to 20 Hz, 14 Hz to 20 Hz, 15 Hz to 20 Hz, 17 Hz to 20 Hz, 18 Hz to 20 Hz, or 19 Hz to 20 Hz. In some embodiments, the post-first electromagnetic field is administered at a nominal frequency in a range of 10 Hz to 19 Hz, 10 Hz to 18 Hz, 10 Hz to 17 Hz, 10 Hz to 16 Hz, 10 Hz to 15 Hz, 10 Hz to 14 Hz, 10 Hz to 13 Hz, 10 Hz to 12 Hz, or 10 Hz to 11 Hz.
[0041] In some embodiments, in a 4-phase protocol, or in a 5-phase protocol, the treatment protocol can comprise applying a pre-second electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, the presecond electromagnetic field does not directly target endometrial tissue. In some embodiments, the selection of the pre-second electromagnetic field nominal frequency range is based on the demonstrated efficacy in promoting chondrogenesis. In some embodiments, the nominal frequencies in the presecond electromagnetic field range can effectively stimulate chondrocytes and enhance ECM synthesis. In some embodiments, the pre-second electromagnetic field's ability to modulate cellular signaling and ion channels can contribute to the therapeutic effect, helping to alleviate pain and support the healing of affected tissues. In some embodiments, by targeting biological processes such as cellularsignaling and ion channels, the pre-second electromagnetic field can be effective in the holistic treatment approach for endometriosis, adenomyosis, or dysmenorrhea complementing the effects of the other electromagnetic fields in the protocol. For example, in some embodiments, in Chondro frequency, or the presecond electromagnetic field, can be used to promote proteoglycan extra-cellular matrix found in connective tissue and cartilage.
[0042] In some embodiments, the pre-second electromagnetic field is administered at a nominal frequency in a range of 65 Hz to 85 Hz, or any range or subrange between 65 Hz and 85 Hz. For example, in some embodiments, the pre-second electromagnetic field is administered at a nominal frequency in a range of 66 Hz to 84 Hz, 67 Hz to 83 Hz, 68 Hz to 82 Hz, 69 Hz to 81 Hz, 70 Hz to 80 Hz, 71 Hz to 79 Hz, 72 Hz to 78 Hz, 73 Hz to 77 Hz, or 74 Hz to 76 Hz. In some embodiments, the pre-second electromagnetic field is administered at a nominal frequency in a range of 65 Hz to 84 Hz, 65 Hz to 83 Hz, 65 Hz to 82 Hz, 65 Hz to 81 Hz, 65 Hz to 80 Hz, 65 Hz to 79 Hz, 65 Hz to 78 Hz, 65 Hz to 77 Hz, 65 Hz to 76 Hz, 65 Hz to 75 Hz, 65 Hz to 74 Hz, 65 Hz to 73 Hz, 65 Hz to 72 Hz, 65 Hz to 71 Hz, 65 Hz to 70 Hz, 65 Hz to 69 Hz, 65 Hz to 68 Hz, 65 Hz to 67 Hz, or 65 Hz to 66 Hz. In some embodiments, the pre-second electromagnetic field is administered at a nominal frequency in a range of 66 Hz to 85 Hz, 67 Hz to 85 Hz, 68 Hz to 85 Hz, 69 Hz to 85 Hz, 70 Hz to 85 Hz, 71 Hz to 85 Hz, 72 Hz to 85 Hz, 73 Hz to 85 Hz, 74 Hz to 85 Hz, 75 Hz to 85 Hz, 76 Hz to 85 Hz, 77 Hz to 85 Hz, 78 Hz to 85 Hz, 79 Hz to 85 Hz, 80 Hz to 85 Hz, 81 Hz to 85 Hz, 80 Hz to 85 Hz, 81 Hz to 85 Hz, 82 Hz to 85 Hz, 83 Hz to 85 Hz or 84 Hz to 85 Hz.
[0043] In some embodiments, in a 5-phase treatment protocol, after applying the presecond electromagnetic field, the treatment protocol can comprise applying the first electromagnetic field at or near the site of pain in the subject in need thereof. In some embodiments, the first electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 70 Hz. For example, in some embodiments after applying the pre-second electromagnetic field, the treatment protocol can comprise applying the first electromagnetic field at a nominal frequency in a range of 40 Hz to 70 Hz.
[0044] In some embodiments, the nominal frequency can have a variation. For example, when the nominal frequency is specified at 57 Hz, for example, a small range of frequencies surrounding that nominal frequency will suffice and may be referred to as "about" 57 Hz.
[0045] In some embodiments, at low frequency, frequency below 50 Hz, the low frequency can be more sensitive due to a reliance on precise timing for effects like ion channel modulation and cellular signaling. In some embodiments, a frequency below 50 Hz, can have a variance from about ±1-2 Hz of the nominal frequency. In some embodiments, the small range can ensure the nominal frequency remains within the optimal zone for osteoblast activation, epithelial repair, or cytokine modulation.
[0046] In some embodiments, at mid frequency, frequency from about 51 Hz to about 100 Hz, the mid frequency can be slightly more forgiving in variance compared to low frequency due to broader cellular responsiveness at this range. In some embodiments, a frequency from about 51 Hz to about 100 Hz, can have a variance from about ±3-5 Hz of the nominal frequency. In some embodiments, chondrocyte activity and ECM production can tolerate slight shifts without substantially diminishing efficacy.
[0047] In some embodiments, at low frequency, frequency below 1000 Hz, the low frequency can have a broader variance compared to high frequency and mid frequency. In some embodiments, low frequencies target broader systems like nerve modulation. In some embodiments, small deviations to low frequencies can be less likely to impact therapeutic outcomes. In some embodiments, a frequency above 100 Hz, can have a variance from about ±5-10 Hz of the nominal frequency. In some embodiments, neural pathways can be responsive across a range of high frequencies, making the high frequency range more adaptable.
[0048] In some embodiments, the nominal frequency can decay. In some embodiments, the decay, or the reduction in strength of the electromagnetic fields described herein, can occur due to the distance from the area of the pain, the subject’s bodyability to absorb the electromagnetic waves, or the time of each protocol being administered to the subject’s body.
[0049] In some embodiments, the first electromagnetic field decays in a range of ± 1-2 below 50 Hz and in a range of ± 3-5 above 50 Hz. For example, in some embodiments, a nominal frequency of 46 for the first electromagnetic field, can begin to decay at least at 44 Hz, 45 Hz, 47 Hz, 48 Hz, or any combination thereof. In some embodiments, the second electromagnetic field decays in range of ± 3-5 above 50 Hz. In some embodiments, the post-first electromagnetic field decays in ± 3-5 above 50 Hz. In some embodiments, the pre-second electromagnetic field decays in ± 5-10 above 100 Hz.
[0050] In some embodiments, the first electromagnetic field, the second electromagnetic field, the pre-treatment electromagnetic field, and the pre-second electromagnetic field are mapped to endometrial inflammatory markers. The endometrial inflammatory markers can be at least one of an TNF- a, IL-1 p, lnterleukin-4 (IL-4), IL-6, IL-8, IL-10, a C-reactive protein (CRP), or any combination thereof.
[0051] In some embodiments, the treatment protocol is applied for a time period of about 20 minutes to 360 minutes, or any range or subrange between 20 minutes and 360 minutes. For example, in some embodiments, the treatment protocol is applied for a time period of about 40 minutes to 340 minutes, 60 minutes to 320 minutes, 80 minutes to 300 minutes, 100 minutes to 280 minutes, 120 minutes to 260 minutes, 140 minutes to 240 minutes, 160 minutes to 220 minutes, or 180 minutes to 200 minutes. In some embodiments, the treatment protocol is applied for a time period of about 40 minutes to 360 minutes, 60 minutes to 360 minutes, 80 minutes to 360 minutes, 100 minutes to 360 minutes, 120 minutes to 360 minutes, 140 minutes to 360 minutes, 160 minutes to 360 minutes, 180 minutes to 360 minutes, 200 minutes to 360 minutes, 220 minutes to 360 minutes, 240 minutes to 360 minutes, 260 minutes to 360 minutes, 280 minutes to 360 minutes, 300 minutes to 360 minutes, 320 minutes to 360 minutes, or 340 minutes to 360 minutes. In some embodiments, the treatment protocol is applied for a time period of about 20 minutes to 340 minutes, 20 minutes to 320 minutes, 20 minutes to 300 minutes,20 minutes to 280 minutes, 20 minutes to 260 minutes, 20 minutes to 240 minutes, 20 minutes to 220 minutes, 20 minutes to 200 minutes, 20 minutes to 180 minutes, 20 minutes to 160 minutes, 20 minutes to 140 minutes, 20 minutes to 120 minutes, 20 minutes to 100 minutes, 20 minutes to 80 minutes, 20 minutes to 60 minutes, or 20 minutes to 40 minutes.
[0052] In some embodiments, the treatment protocol is applied incrementally for a time period of 1 minute to 20 minutes, or any range or subrange between 1 minute and 20 minutes. For example, in some embodiments, the treatment protocol incrementally for a time period of 2 m inutes to 18 m inutes, 4 m inutes to 16 m inutes, 6 minutes to 14 minutes, or 8 minutes to 12 minutes. In some embodiments, the treatment protocol incrementally for a time period of 1 minute to 18 minutes, 1 minute to 16 minutes, 1 minute to 14 minutes, 1 minute to 12 minutes, 1 minute to 10 minutes, 1 minute to 8 minutes, 1 minute to 6 minutes, 1 minute to 4 minutes, or 1 minute to 2 minutes.
[0053] In some embodiments, at least one of the first electromagnetic field, the second electromagnetic field, the pre-treatment electromagnetic field, the pre-second electromagnetic field, or any combination thereof is applied for a precise time. In some embodiments, the first electromagnetic field can be applied for 30 minutes. In some embodiments, the second electromagnetic field can be applied for 10 minutes. In some embodiments, the pre-treatment electromagnetic field can be applied for 20 minutes. In some embodiments, the pre-second electromagnetic field can be applied for 10 minutes.
[0054] In some embodiments, in between applying at least one of the first electromagnetic field, the second electromagnetic field, the pre-treatment electromagnetic field, the pre-second electromagnetic field, or any combination thereof, the treatment protocol comprises a rest period of 1 minute to 5 minutes, or any range or subrange between 1 minute and 5 minutes. For example, in some embodiments, the treatment protocol comprises a rest period of 2 minutes to 4 minutes, 1 minute to 4 minutes, 1 minute to 3 minutes, 1 minute to 2 minutes, 2 minutes to 5 minutes, 3 minutes to 4 minutes, or 4 minutes to 5 minutes.
[0055] In some embodiments, the treatment protocol is applied 1 to 4 times per day, or any range or subrange between 1 and 4 times per day. For example, in some embodiments, the treatment protocol is applied 2 to 3, 1 to 3, 1 to 2, 2 to 4, or 3 to 4 times per day.
[0056] Some embodiments relate to a method. In some embodiments, the method comprises positioning a pulsed electromagnetic field device, described herein at or near a site of pain and applying a treatment protocol.
[0057] In some embodiments, the electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 175 Hz, or any range or subrange between 40 Hz to 175 Hz. For example, in some embodiments, the electromagnetic field is administered at a nominal frequency in a range of 50 Hz to 165 Hz, 60 Hz to 155 Hz, 70 Hz to 145 Hz, 80 Hz to 135 Hz, 90 Hz to 125 Hz, 100 Hz to 115 Hz, or 105 Hz to 110 Hz. In some embodiments, the electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 165 Hz, 40 Hz to 155 Hz, 40 Hz to 145 Hz, 40 Hz to 135 Hz, 40 Hz to 125 Hz, 40 Hz to 115 Hz, 40 Hz to 105 Hz, 40 Hz to 95 Hz, 40 Hz to 85 Hz, 40 Hz to 75 Hz, 40 Hz to 65 Hz, or 40 Hz to 55 Hz. In some embodiments, the electromagnetic field is administered at a nominal frequency in a range of 50 Hz to 175 Hz, 60 Hz to 175 Hz, 70 Hz to 175 Hz, 80 Hz to 175 Hz, 90 Hz to 175 Hz, 100 Hz to 175 Hz, 110 Hz to 175 Hz, 120 Hz to 175 Hz, 130 Hz to 175 Hz, 140 Hz to 175 Hz, 150 Hz to 175 Hz, 160 Hz to 175 Hz, or 170 Hz to 175 Hz.
[0058] In some embodiments, the electromagnetic field comprises an Angio frequency at a nominal frequency in a range of 40 Hz to 70 Hz, or any range or subrange between 40 Hz and 70 Hz as described herein. In some embodiments, the electromagnetic field comprises a pain frequency at a nominal frequency in a range of 125 Hz to 175 Hz, or any range or subrange between 125 Hz and 175 Hz as described herein.
[0059] In some embodiments, the electromagnetic field comprises an osseus frequency at a nominal frequency in a range of 10 Hz to 20 Hz, or any range or subrange between 10 Hz and 20 Hz as described herein. In some embodiments, theelectromagnetic field comprises a Chondro frequency at a nominal frequency in a range of 65 Hz to 85 Hz, or any range or subrange between 65 Hz and 85 Hz as described herein.
[0060] In some embodiments, the treatment protocol is applied for a time period of about 20 minutes to 360 minutes, or any range or subrange between 20 minutes and 360 minutes as described herein.
[0061] In some embodiments, the treatment protocol is applied incrementally for a time period of 1 minute to 20 minutes, or any range or subrange between 1 minute and 20 minutes as described herein.
[0062] In some embodiments, the electromagnetic field is mapped to endometrial inflammatory markers. In some embodiments, the endometrial inflammatory markers are at least one of an IL-6, a CRP, or any combination thereof.
[0063] In some embodiments, the pulsed electromagnetic field device is in operation for a time period of about 1 minute to 20 minutes, or any range or subrange between 1 minute and 20 minutes. For example, in some embodiments, the pulsed electromagnetic field device is in operation for a time period of 2 minutes to 18 minutes, 4 minutes to 16 minutes, 6 minutes to 14 minutes, or 8 minutes to 12 minutes. In some embodiments, the pulsed electromagnetic field device is in operation for a time period of 1 minute to 18 minutes, 1 minute to 16 minutes, 1 minute to 14 minutes, 1 minute to 12 minutes, 1 minute to 10 minutes, 1 minute to 8 minutes, 1 minute to 6 minutes, 1 minute to 4 minutes, or 1 minute to 2 minutes.
[0064] In some embodiments, the pulsed electromagnetic field device is applied for a time period at a ratio of the Angio frequency to the pain frequency of 1 :2 to 1 :4, or any range or subrange between 1 :2 and 1 :4. For example, in some embodiments, the pulsed electromagnetic field device is applied for a time period at a ratio of the Angio frequency to the pain frequency of 1 :2 to 1 :3 or 1 :3 to 1 :4.
[0065] Any one or more of the embodiments disclosed herein shall be understood to be combinable without departing from the scope or spirit of the disclosure.
[0066] ASPECTS
[0067] Various Aspects are described below. It is to be understood that any one or more of the features recited in the following Aspect(s) can be combined with any one or more other Aspect(s).Aspect 1. A method comprising:positioning a pulsed electromagnetic field device at or near a site of pain, wherein the site of pain is at least one of an abdomen, a pelvis, a lower back, or any combination thereof; andapplying a treatment protocol, wherein the treatment protocol comprises:a) applying a first electromagnetic field at or near the site of pain in the subject in need thereof,wherein the first electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 70 Hz; and b) applying a second electromagnetic field at or near the site of pain in the subject in need thereof,wherein the second electromagnetic field is administered at a nominal frequency in a range of 70 Hz to 175 Hz; wherein the treatment protocol is applied for a time period of about 20 minutes to 360 minutes.Aspect 2. The method according to Aspect 1, wherein the treatment protocol is applied incrementally for a time period of 1 minute to 20 minutes.Aspect 3. The method according to any one of Aspects 1 -2, wherein after applying the second electromagnetic field, the treatment protocol further comprises:a) applying a pre-treatment electromagnetic field at or near the site of pain in the subject in need thereof,wherein the pre-treatment electromagnetic field is administered at a nominal frequency in a range of 10 Hz to 20 Hz; andb) applying a pre-second electromagnetic field at or near the site of pain in the subject in need thereof,wherein the pre-second electromagnetic field is administered at a nominal frequency in a range of 65 Hz to 85 Hz.Aspect 4. The method according to any one of Aspects 1 -3, wherein after applying the second electromagnetic field, the method further comprises:applying the first electromagnetic field at or near the site of pain in the subject in need thereof,wherein the first electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 70 Hz.Aspect s. The method according to any one of Aspects 1-4, wherein the first electromagnetic field is configured to target an inflammatory phase of an endometrial tissue.Aspect s. The method according to any one of Aspects 1-5, wherein the second electromagnetic field is configured to target a pain phase of an endometrial tissue.Aspect 7. The method according to any one of Aspects 1-6, wherein the first electromagnetic field and the second electromagnetic field are mapped to endometrial inflammatory markers.Aspect 8. The method according to any one of Aspects 1-7, wherein the endometrial inflammatory markers are at least one of an TNF- a, IL-1 (3, lnterleukin-4 (IL-4), IL-6, IL-8, IL-10, a C-reactive protein (CRP), or any combination thereof.Aspect s. The method according to any one of Aspects 1-8, wherein the pulsed electromagnetic field device is in operation for a time period of about 1 minute to 20 minutes.Aspect 10. The method according to any one of Aspects 1-9, wherein the pulsed electromagnetic field device is applied for a time period at a ratio of the first electromagnetic field to the second electromagnetic field of 1 :2 to 1 :4.Aspect 11. A method comprising:positioning a pulsed electromagnetic field device at or near a site of pain, wherein the site of pain is at least one of an abdomen, a pelvis, a lower back, or any combination thereof; andapplying a treatment protocol, wherein the treatment protocol comprises:applying a electromagnetic field at or near the site of pain in the subject in need thereof,wherein the electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 175 Hz for at time period of 20 minutes to 360 minutes.Aspect 12. The method according to Aspect 11, wherein the treatment protocol is applied incrementally for a time period of 1 minute to 20 minutes.Aspect 13. The method according to any one of Aspect 11-12, wherein the electromagnetic field comprises:an Angio frequency at a nominal frequency in a range of 40 Hz to 70 Hz; anda pain frequency at a nominal frequency in a range of 125 Hz to 175 Hz. Aspect 14. The method according to any one of Aspect 11-13, wherein the electromagnetic field is configured to target at least one of an inflammatory phase of an endometrial tissue, a pain phase of an endometrial tissue, or any combination thereof. Aspect 15. The method according to any one of Aspect 11-14, wherein the electromagnetic field is configured to target at least one of an osseus phase, a Chondro phase, or any combination thereof.Aspect 16. The method according to any one of Aspect 11-15, wherein the electromagnetic field comprises:an osseus frequency at a nominal frequency in a range of 10 Hz to 20 Hz; anda Chondro frequency at a nominal frequency in a range of 65 Hz to 85 Hz.Aspect 17. The method according to any one of Aspect 11-16, wherein the electromagnetic field is mapped to endometrial inflammatory markers.Aspect 18. The method according to any one of Aspect 11-17, wherein the endometrial inflammatory markers are at least one of an TNF- a, IL-1 (3, lnterleukin-4 (IL-4), IL-6, IL-8, IL-10, a C-reactive protein (CRP), or any combination thereof.Aspect 19. The method according to any one of Aspect 11-18, wherein the pulsed electromagnetic field device is in operation for a time period of about 1 minute to 20 minutes.Aspect 20. The method according to any one of Aspect 11-19, wherein the pulsed electromagnetic field device is applied for a time period at a ratio of the Angio frequency to the pain frequency of 1 :2 to 1 :4.
Claims
CLAIMSWHAT IS CLAIMED IS:
1. A method comprising:positioning an electromagnetic field device at or near a site of menstrual pain in a subject in need thereof,wherein the site of menstrual pain is at least one of an abdomen, a pelvis, a lower back, or any combination thereof,wherein the menstrual pain comprises at least one of an endometriosis, an adenomyosis, a dysmenorrhea, or any combination thereof; and applying a treatment protocol, wherein the treatment protocol comprises:a) applying a first electromagnetic field at or near the site of pain in the subject in need thereof,wherein the first electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 70 Hz; andb) applying a second electromagnetic field at or near the site of pain in the subject in need thereof,wherein the second electromagnetic field is administered at a nominal frequency in a range of 70 Hz to 175 Hz;wherein the treatment protocol is applied for a time period of about 20 minutes to 360 minutes.
2. The method of claim 1 , wherein the treatment protocol is applied incrementally for a time period of 1 minute to 20 minutes.
3. The method of claim 1 , wherein after applying the first electromagnetic field, the treatment protocol further comprises:applying a post-first electromagnetic field at or near the site of pain in the subject in need thereof,wherein the post-first electromagnetic field is administered at a nominal frequency in a range of 10 Hz to 20 Hz.
4. The method of claim 3, wherein after applying the post-first electromagnetic field, the treatment protocol further comprises:applying a pre-second electromagnetic field at or near the site of pain in the subject in need thereof,wherein the pre-second electromagnetic field is administered at a nominal frequency in a range of 65 Hz to 85 Hz.
5. The method of claim 1 , wherein after applying the second electromagnetic field, the method further comprises:applying the first electromagnetic field at or near the site of pain in the subject in need thereof,wherein the first electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 70 Hz.
6. The method of claim 1 , wherein the first electromagnetic field is configured to target an inflammatory phase of an endometrial tissue.
7. The method of claim 1 , wherein the second electromagnetic field is configured to target a pain phase of an endometrial tissue.
8. The method of claim 1 , wherein the first electromagnetic field and the second electromagnetic field are mapped to endometrial inflammatory markers.
9. The method of claim 7, wherein the endometrial inflammatory markers are at least one of an TNF- a, IL-1 p, lnterleukin-4 (IL-4), IL-6, IL-8, IL-10, a C-reactive protein (CRP), or any combination thereof.
10. The method of claim 1 , wherein the electromagnetic field device is in operation for a time period of about 1 minute to 20 minutes.
11. The method of claim 1, wherein the electromagnetic field device is applied for a time period at a ratio of the first electromagnetic field to the second electromagnetic field of 1:2 to 1:4.
12. A method comprising:positioning an electromagnetic field device at or near a site of pain,wherein the site of pain is at least one of an abdomen, a pelvis, a lower back, or any combination thereof; andapplying a treatment protocol, wherein the treatment protocol comprises:applying an electromagnetic field at or near the site of pain in the subject in need thereof,wherein the electromagnetic field is administered at a nominal frequency in a range of 40 Hz to 175 Hz for at time period of 20 minutes to 360 minutes.
13. The method of claim 11, wherein the treatment protocol is applied incrementally for a time period of 1 minute to 20 minutes.
14. The method of claim 11 , wherein the electromagnetic field comprises:an Angio frequency at a nominal frequency in a range of 40 Hz to 70 Hz; and a pain frequency at a nominal frequency in a range of 70 Hz to 175 Hz.
15. The method of claim 11, wherein the electromagnetic field is configured to target at least one of an inflammatory phase of an endometrial tissue, a pain phase of an endometrial tissue, or any combination thereof.
16. The method of claim 14, wherein the electromagnetic field is configured to target at least one of an Osseus phase, a Chondro phase, or any combination thereof.
17. The method of claim 13, wherein the electromagnetic field comprises:an Osseus frequency at a nominal frequency in a range of 10 Hz to 20 Hz; and a Chondro frequency at a nominal frequency in a range of 65 Hz to 85 Hz.
18. The method of claim 11, wherein the electromagnetic field is mapped to endometrial inflammatory markers.
19. The method of claim 17, wherein the endometrial inflammatory markers are at least one of an TNF- a, IL-1 [3, lnterleukin-4 (IL-4), IL-6, IL-8, IL-10, a C-reactive protein (CRP), or any combination thereof.
20. The method of claim 11, wherein the electromagnetic field device is in operation for a time period of about 1 minute to 20 minutes.21.The method of claim 13, wherein the electromagnetic field device is applied for a time period at a ratio of the Angio frequency to the pain frequency of 1 :2 to 1 :4.
